Insulet (PODD) to Post Earnings on Wednesday

Insulet (NASDAQ:PODD) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $1.45 per share and revenue of $787.3890 million for the quarter. Insulet has set its FY 2026 guidance at 6.210- EPS. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the company posted $1.02 EPS. On average, analysts expect Insulet to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Insulet Price Performance

PODD stock opened at $165.35 on Monday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $155.26 and its 200 day moving average is $197.67. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of 38.45, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. Insulet has a 1-year low of $138.79 and a 1-year high of $354.88.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: UBS Group began research coverage of Insulet, potentially increasing institutional visibility and investor attention. However, the available report does not disclose UBS’s rating or price target. Insulet research coverage started at UBS Group
• Neutral Sentiment: The legal notices concern alleged violations of federal securities laws by Insulet and certain executives. The allegations have not been proven, and the financial impact of the litigation remains uncertain. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: Several firms, including Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Bleichmar Fonti & Auld, Schall Brown & Schwartz, DJS Law Group, Rosen Law Firm, and Glancy Prongay, publicized the pending class action. The notices generally cover investors who purchased Insulet securities between February 21 or May 21, 2025, and May 26, 2026, and allege investor losses related to disclosures involving defective Omnipod manufacturing controls. Bleichmar Fonti & Auld securities lawsuit notice
• Negative Sentiment: The concentration of similar legal announcements may amplify concerns about potential damages, management accountability, regulatory scrutiny, and reputational risk, even though no judgment or settlement has been reported. Insulet investor alert from Schall Brown & Schwartz

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PODD. RTW Investments LP bought a new position in Insulet during the fourth quarter valued at approximately $92,264,000. AQR Capital Management LLC grew its position in Insulet by 161.6% in the 4th quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock worth $130,499,000 after purchasing an additional 283,643 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in Insulet during the 2nd quarter valued at $80,082,000. Squarepoint Ops LLC raised its stake in Insulet by 11,905.8% during the 3rd quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after buying an additional 225,377 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Insulet by 37.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after buying an additional 156,009 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PODD. Bank of America cut their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Royal Bank Of Canada reduced their target price on Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Robert W. Baird lowered their price target on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Evercore set a $180.00 price target on Insulet in a research note on Monday, July 6th. Finally, Leerink Partners cut their price objective on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.38.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.